Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07465757) titled 'A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)' on March 6.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Puma Biotechnology, Inc.
Condition:
Small Cell Lung Cancer ( SCLC )
Intervention:
Drug: Alisertib
Drug: Alisertib
Drug: Alisertib
Drug: Alisertib
Drug: Alisertib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 30, 2026
Target Sample Size: 50
To know more, visit https://clinicaltrials.gov/...